Using this combination in an NSG mouse model of prostate cancer xenograft demonstrated that while in the presence of HER2-CAR-T cells, the CAd-VECPDL1 virus’s expression of anti-PD-L1 antibody at the tumor site was significantly more effective at reducing tumor size. Here, ERBB2 is linked to neoplasm.